Gavazzi A, Marioni R, Campana C, Montemartini C
Division of Cardiology, Scientific Institute of the Polyclinic of S. Matteo, Pavia, Italy.
J Hypertens Suppl. 1994 Jul;12(4):S89-93.
To compare the efficacy and safety of captopril twice a day with quinapril once a day for the treatment of mild to moderate congestive heart failure in a multicentre, double-blind, randomly allocated, parallel-group, 12-week study.
Exercise capacity, M-mode echocardiographic left ventricular measurements and clinical signs and symptoms were evaluated. After a 2-week, single-blind, placebo washout period, the patients were randomly allocated to double-blind treatment with either captopril twice a day or quinapril once a day; the initial doses of 12.5 and 5 mg, respectively, were increased to 25 and 10 mg, respectively, in the first month, and 50 and 20 mg in the second and third months, as required to achieve adequate blood pressure control. Baseline diuretic and/or digitalis therapy was allowed during the study, so that the patients were maintained in a stable condition.
Data from 70 captopril- and 76 quinapril-treated patients were analysed. Both angiotensin converting enzyme inhibitors displayed comparable efficacy. Both drugs were well tolerated, with a low drop-out rate (11.4% for captopril and 10.5% for quinapril).
Treatment with 20 mg quinapril once a day was as effective and safe for the treatment of congestive heart failure as 100 mg captopril administered twice a day.
在一项多中心、双盲、随机分配、平行组、为期12周的研究中，比较每日两次服用卡托普利与每日一次服用喹那普利治疗轻至中度充血性心力衰竭的疗效和安全性。
评估运动能力、M型超声心动图测量的左心室指标以及临床体征和症状。经过为期2周的单盲安慰剂洗脱期后，患者被随机分配接受双盲治疗，分别为每日两次服用卡托普利或每日一次服用喹那普利；初始剂量分别为12.5 mg和5 mg，在第一个月分别增至25 mg和10 mg，在第二和第三个月根据需要增至50 mg和20 mg，以实现充分的血压控制。研究期间允许维持基线利尿剂和/或洋地黄治疗，以便患者保持稳定状态。
分析了70例接受卡托普利治疗和76例接受喹那普利治疗患者的数据。两种血管紧张素转换酶抑制剂显示出相当的疗效。两种药物耐受性良好，脱落率低（卡托普利为11.4%，喹那普利为10.5%）。
每日一次服用20 mg喹那普利治疗充血性心力衰竭的疗效和安全性与每日两次服用100 mg卡托普利相当。
